Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025Management ViewChristophe Weber, CEO, announced his retirement ...

A panelist discusses how caregivers can support patients with polycythemia vera (PV) by helping track symptoms, managing medical appointments and recognizing warning signs that require physician ...

When Takeda CEO Christophe Weber retires from the company in June 2026, a familiar face among the Massachusetts biotech scene will take over leading the Japanese pharma giant.

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (SLN – Research Report) and keeping the price ...

H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating and $75 price target on Silence Therapeutics (SLN) shares following a recent ...

I am a 66-year-old white male who is active and relatively healthy. I have recently been diagnosed with prostate cancer. One ...

As you say, not all trials found a benefit, but the largest trial found that intrathecal injections — which are similar to ...

Finally, Protagonist Therapeutics (NASDAQ:PTGX) has indicated that its financial runway extends beyond the fourth quarter of 2028, providing the company with a stable foundation to continue its ...

Merit Financial Group LLC bought a new stake in shares of Incyte Co. (NASDAQ:INCY – Free Report) in the 4th quarter, ...

Disc Medicine is in strong financial shape, advancing key candidates. Find out why IRON stock could be a strong investment ...

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. | “There's an evolution of our economic model that starts with IRA, and will get worse and ...

Shares of Incyte INCY have risen 15.3% in the past twelve months against the industry’s decline of 14.3%. The stock has ...